GenePOC Announces Setup of an Extensive Network of Commercial Partners Across Europe for Distribution

QUÉBEC, November 3, 2016 /PRNewswire/ --

GenePOC, which is ready to commercialize its first molecular solution for Clostridium difficile identification in Europe, is proud to announce that it has signed 8 distribution partners to cover the Western European market. 

GenePOC, Inc. (GenePOC) has announced that it signed distribution agreements with 8 partners across Europe for the commercialization of its first products. This is a key Milestone in the development of GenePOC and the timing fits well with the timeline announced earlier to start commercialization in autumn of 2016.

The commercial partners signed up are Astra Formedic S.r.l.in Italy, bestbion dx GmbH in Germany/Austria, Biosynex Group in France, EMM Life Science AB in Sweden/Denmark/Finland/Norway/Iceland, Fannin Ltd in Ireland, Mediphos Group BV in Netherlands/Belgium/Luxembourg, Near Patient Diagnostics Ltd in the UK and Vitro S.A.B. de C.V. in Spain/Portugal.

The knowledge and position of these partners in the market combined with their dedication, enthusiasm and confidence in GenePOC will allow the company to tackle the next key steps on the road to commercial success in the best possible conditions. GenePOC's partners have a strong position in infectious disease, molecular diagnostics and/or Point-of-care, giving GenePOC great confidence for a solid entry and rapid expansion into the European Market through these collaborations.

"We are delighted with the collaborations signed and the enthusiasm of our Partners that we experienced during our first distributors' meeting in preparation for product launch that we held in the first week of October," said Patrice Allibert CEO of GenePOC.

About GenePOC 

GenePOC is a company that specializes in the development of rapid diagnostic devices which enable the prevention and detection of infectious diseases. GenePOC is a member (majority owned) of the Debiopharm Group.

The company devised the GenePOC Diagnostics system, enabling rapid microbial testing at the point of care (POC). This instrument can analyses any type of infection in no more than an hour, is easy to operate and deals with a wide range of biological samples, making it a user-friendly and efficient tool.

In 2013, Frost & Sullivan recognized GenePOC by presenting it with the 2013 Best Practices Award North American Molecular Diagnostics Entrepreneurial Company of the Year. 

Further information: http://www.genepoc-diagnostics.com/

About Debiopharm Group 

Debiopharm Group™ is a Swiss-headquartered global biopharmaceutical group of five companies active worldwide in the development and manufacture of drugs and diagnostic tools. Debiopharm focuses on developing prescription drugs and diagnostics that target unmet medical needs. The group in-licenses and develops promising drug candidates. The products are commercialized by out-licensing partners and distribution partners to give access to the largest number of patients worldwide.

For more information, please see http://www.debiopharm.com

We are on Twitter. Follow @DebiopharmNews at http://twitter.com/DebiopharmNews

Contact at Debiopharm International SA
Christelle Tur
Communications Coordinator
christelle.tur@debiopharm.com

Tel.: +41 (0)21-321-01-11

Contact at GenePOC
Patrice Allibert
CEO
patrice.allibert@genepoc.ca 
Tel.: +1-418-650-3535